Credit Suisse Group Analysts Give Novartis (VTX:NOVN) a CHF 88 Price Target

Credit Suisse Group set a CHF 88 target price on Novartis (VTX:NOVN) in a report released on Friday, Borsen Zeitung reports. The firm currently has a neutral rating on the stock.

Several other research analysts have also commented on the company. JPMorgan Chase & Co. set a €50.00 ($58.14) target price on Brenntag and gave the stock a buy rating in a research report on Tuesday, July 16th. Barclays lifted their target price on from $65.00 to $100.00 and gave the stock an overweight rating in a research report on Friday. UBS Group reiterated a neutral rating on shares of CAIXABANK/ADR in a research report on Thursday. Kepler Capital Markets set a €160.00 ($186.05) target price on Pfeiffer Vacuum Technology and gave the stock a buy rating in a research report on Tuesday, May 21st. Finally, HSBC set a €101.00 ($117.44) target price on Grenke and gave the stock a buy rating in a research report on Thursday, April 25th. Three investment analysts have rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company. The stock has an average rating of Hold and a consensus target price of CHF 88.64.

Novartis has a 12 month low of CHF 72.45 and a 12 month high of CHF 88.30.

About Novartis

Novan, Inc, a clinical-stage biotechnology company, focuses on the development and commercialization of nitric oxide-based therapies to treat dermatological and oncovirus-mediated diseases. Its clinical stage product candidates include SB204, a topical monotherapy that is in Phase III pivotal clinical trials for the treatment of acne vulgaris; and SB206, a topical antiviral gel, which is in Phase III pivotal trials for the treatment of patients with external genital warts, and Phase II clinical trial for the treatment of molluscum contagiosum.

Recommended Story: What is the return on assets (ROA) ratio?

Analyst Recommendations for Novartis (VTX:NOVN)

Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.